{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:17Z","timestamp":1793155817487,"version":"4.5.0"},"reference-count":75,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"UCB Pharma"},{"name":"UCB Pharma"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1080\/1744666x.2023.2277266","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T14:17:57Z","timestamp":1698848277000},"page":"155-168","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Bimekizumab for the treatment of psoriatic arthritis"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan","family":"Shaw","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"e_1_3_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30830-4"},{"key":"e_1_3_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.01.003"},{"key":"e_1_3_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"e_1_3_10_6_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-65"},{"key":"e_1_3_10_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201706"},{"key":"e_1_3_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.001"},{"key":"e_1_3_10_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01558"},{"key":"e_1_3_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08902.x"},{"key":"e_1_3_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.03.035"},{"key":"e_1_3_10_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585134"},{"key":"e_1_3_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.05.010"},{"key":"e_1_3_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948138"},{"key":"e_1_3_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894"},{"key":"e_1_3_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176401"},{"key":"e_1_3_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3794"},{"key":"e_1_3_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_3_10_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127"},{"key":"e_1_3_10_20_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0094-4"},{"key":"e_1_3_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211037846"},{"key":"e_1_3_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.038"},{"key":"e_1_3_10_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001306"},{"key":"e_1_3_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3908-y"},{"key":"e_1_3_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00443-y"},{"key":"e_1_3_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02302-9"},{"key":"e_1_3_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02303-0"},{"key":"e_1_3_10_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"e_1_3_10_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"e_1_3_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40851"},{"key":"e_1_3_10_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"},{"key":"e_1_3_10_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"e_1_3_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40226"},{"key":"e_1_3_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"e_1_3_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"e_1_3_10_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_3_10_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_3_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"e_1_3_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"e_1_3_10_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221048"},{"key":"e_1_3_10_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"e_1_3_10_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219014"},{"key":"e_1_3_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"e_1_3_10_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"e_1_3_10_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_3_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_3_10_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"e_1_3_10_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216835"},{"key":"e_1_3_10_49_1","unstructured":"ClinicalTrials.gov. A study to assess the long-term safety tolerability and efficacy of bimekizumab in the treatment of subjects with active psoriatic arthritis (BE VITAL) ClinicalTrials.Gov[updated July 7 2023]. [cited 2023 Jul 11]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04009499"},{"key":"e_1_3_10_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/msc.1694"},{"key":"e_1_3_10_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_3_10_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13185"},{"key":"e_1_3_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33161-7"},{"key":"e_1_3_10_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42280"},{"issue":"9","key":"e_1_3_10_55_1","article-title":"Bimekizumab treatment in biologic DMARD-Na\u00efve patients with active psoriatic arthritis: 52-Week efficacy and safety results from a phase 3, randomized, placebo-controlled, active reference study [abstract]. American College Rheumatology; 2022","volume":"74","author":"Ritchlin C","year":"2022","unstructured":"Ritchlin C, Coates L, McInnes I, et al. editors. Bimekizumab treatment in biologic DMARD-Na\u00efve patients with active psoriatic arthritis: 52-Week efficacy and safety results from a phase 3, randomized, placebo-controlled, active reference study [abstract]. American College Rheumatology; 2022. Arthritis Rheumatol. 2022;74(suppl 9). https:\/\/acrabstracts.org\/abstract\/bimekizumab-treatment-in-biologic-dmard-naive-patients-with-active-psoriatic-arthritis-52-week-efficacy-and-safety-results-from-a-phase-3-randomized-placebo-controlled-active-reference-study\/.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_10_56_1","first-page":"346","article-title":"SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR. EULAR (2023)","volume":"82","author":"Coates LC","year":"2023","unstructured":"Coates LC, Landew\u00e9 R, McInnes IB, et al. SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR. EULAR (2023). Ann Rheum Dis. 2023;82(suppl 1):346\u20137.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_10_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224431"},{"key":"e_1_3_10_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203018"},{"key":"e_1_3_10_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2218086"},{"key":"e_1_3_10_60_1","first-page":"abstract 0511","article-title":"Long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: results from pooled phase 2b\/3 studies [abstract]","volume":"75","author":"Mease P","year":"2023","unstructured":"Mease P, Poddubnyy D, Orbai A-M, et al. Long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: results from pooled phase 2b\/3 studies [abstract]. Arthritis & Rheumat. 2023;75(suppl 9):abstract 0511 .","journal-title":"Arthritis & Rheumat"},{"key":"e_1_3_10_61_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081463"},{"key":"e_1_3_10_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.27"},{"key":"e_1_3_10_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.4204"},{"key":"e_1_3_10_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.2052"},{"issue":"9","key":"e_1_3_10_65_1","article-title":"Achieving increasingly stringent clinical disease control criteria is associated with greater improvements in patient-centric measures of physical function and pain in patients with active PsA: 16-Week results from two phase 3 randomized, placebo-controlled studies [abstract]","volume":"74","author":"Walsh J","year":"2022","unstructured":"Walsh J, Coates LC, Mease PJ, et al. editors. Achieving increasingly stringent clinical disease control criteria is associated with greater improvements in patient-centric measures of physical function and pain in patients with active PsA: 16-Week results from two phase 3 randomized, placebo-controlled studies [abstract]. Arthritis & Rheumat. 2022 Accessed May 22, 2023; 74(suppl 9). https:\/\/acrabstracts.org\/abstract\/achieving-increasingly-stringent-clinical-disease-control-criteria-is-associated-with-greater-improvements-in-patient-centric-measures-of-physical-function-and-pain-in-patients-with-active-psa-16-wee\/","journal-title":"Arthritis & Rheumat"},{"key":"e_1_3_10_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06529-4"},{"key":"e_1_3_10_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_3_10_68_1","unstructured":"European Medicines Agency (EMA). EMA recommends measures to minimise risk of serious side effects with janus kinase inhibitors for chronic inflammatory disorders 2022 [updated 3 November 2022]. [cited 2023 May 22]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic"},{"key":"e_1_3_10_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"e_1_3_10_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341"},{"key":"e_1_3_10_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383"},{"key":"e_1_3_10_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac089"},{"key":"e_1_3_10_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.063"},{"key":"e_1_3_10_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20827"},{"key":"e_1_3_10_75_1","first-page":"abstract 1433","article-title":"Bimekizumab impact on core group for Research and Assessment of psoriasis and psoriatic arthritis (GRAPPA) domains for patients with psoriatic arthritis: 52-Week results from four phase 3 studies [abstract]","volume":"75","author":"Merola J","year":"2023","unstructured":"Merola J, Mease P, Deodhar A, et al. Bimekizumab impact on core group for Research and Assessment of psoriasis and psoriatic arthritis (GRAPPA) domains for patients with psoriatic arthritis: 52-Week results from four phase 3 studies [abstract]. Arthritis & Rheumat. 2023;75(suppl 9):abstract 1433.","journal-title":"Arthritis & Rheumat"},{"key":"e_1_3_10_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595"},{"issue":"9","key":"e_1_3_10_77_1","article-title":"Bimekizumab maintains improvements in efficacy endpoints and has a consistent safety profile through 52 weeks in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: results from two parallel phase 3 studies [abstract]","volume":"74","author":"Baraliakos X","year":"2022","unstructured":"Baraliakos X, Deodhar A, van der Heijde D, et al. editors: Bimekizumab maintains improvements in efficacy endpoints and has a consistent safety profile through 52 weeks in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: results from two parallel phase 3 studies [abstract]. Arthritis & Rheumat. 2022 Accessed Sep 14, 2023; 74(suppl 9). https:\/\/acrabstracts.org\/abstract\/bimekizumab-maintains-improvements-in-efficacy-endpoints-and-has-a-consistent-safety-profile-through-52-weeks-in-patients-with-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis-resu\/","journal-title":"Arthritis & Rheumat"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2023.2277266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T04:55:52Z","timestamp":1727240152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2023.2277266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1080\/1744666X.2023.2277266"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2023.2277266","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}